NEW YORK (GenomeWeb News) – Oncodesign today announced an agreement with Eisai to assess the use of Halaven Injection (eribulin) in earlier line treatment of metastatic breast cancer. 

Oncodesign will conduct in vivo pharmacology studies and Eisai will perform gene expression profiling analysis using Oncodesign's patient-derived xenograft models to evaluate Eisai's Halaven, a non-taxane microtubule dynamics inhibitor. Oncodesign could receive up to €1.25 million ($1.56 million) in revenue for its contributions and has received €900,000 to date, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.